Brief: Alto Neuroscience Receives FDA Fast Track Designation For Alto-101
03/10/2025 13:04
Oct 3 (Reuters) - Alto Neuroscience Inc ANRO.N: ALTO NEUROSCIENCE RECEIVES FDA FAST TRACK DESIGNATION FOR ALTO-101 FOR THE TREATMENT OF COGNITIVE IMPAIRMENT ASSOCIATED WITH SCHIZOPHRENIA Source text: ID:nBw5m4sQGa Further company coverage: ANRO.N ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Alto Neuroscience
See all newsBrief: Alto Neuroscience Promotes Nick Smith To President And Chief Financial Officer
U.S. RESEARCH ROUNDUP-Airbnb, Five Below, Silgan Holdings
Brief: Alto Neuroscience - Proposed Resale Of Up To 6 Million Shares Of Common Stock By Selling Stockholders - SEC Filing
U.S. RESEARCH ROUNDUP-Doordash, Phillips 66, United Therapeutics
Brief: Alto Neuroscience Reports Topline Data From Phase 2 Proof-Of-Concept Study Of Alto-101 And Highlights Pipeline Advancements